Search
Search Results
##search.searchResults.foundPlural##
-
MOLECULAR MECHANISMS OF INHIBITOR DEVELOPMENT IN HEMOPHILIA Guest Editor: Giancarlo Costaman
3496PDF: 1652HTML: 679 -
NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL
2615PDF: 878HTML: 9057Efremov 1: 254Efremov 2: 216 -
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2287PDF: 1838HTML: 838 -
TYROSINE KINASE INHIBITORS AND INTERFERON
2948PDF: 1473HTML: 3098Cover Letter: 234 -
TYROSINE KINASE INHIBITORS AND PREGNANCY
3744PDF: 1721HTML: 2693 -
Guest Editor: G. Castaman GENE THERAPY FOR HEMOPHILIA: FACTS AND QUANDARIES IN THE 21ST CENTURY GENE THERAPY FOR HEMOPHILIA
2233PDF: 1979HTML: 524 -
Acquired Hemophilia A successfully treated with rituximab
2187PDF: 1184HTML: 1516Figure 1: 214 -
OPTIMIZING TREATMENT, MINIMIZING RISK: THERAPEUTIC DRUG MONITORING IN HEMATOLOGICAL MALIGNANCIES
1625PDF: 1873Suppl. Files: 182HTML: 107 -
MUTATIONAL PROFILES OF F8 AND F9 IN A COHORT OF HAEMOPHILIA A AND HAEMOPHILIA B PATIENTS IN THE MULTI-ETHNIC MALAYSIAN POPULATION
2140PDF: 1094HTML: 960Figure 1: 190Figure 2: 207 -
TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA
3468PDF: 1522HTML: 4081 -
NOVEL DRUGS IN FOLLICULAR LYMPHOMA
5785PDF: 1566HTML: 1663Untitled: 258 -
THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA
2561PDF: 821HTML: 1746 -
NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES
2083PDF: 1607HTML: 804 -
-
DRUG THERAPY IN THE PROGRESSED CML PATIENT WITH MULTI-TKI FAILURE
277817PDF: 1849HTML: 3898 -
OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE
2337PDF: 1090HTML: 2026Characteristic of study group: 220 -
ROLE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
2996PDF: 1319HTML: 2834Figure 1: 199 -
HIV INFECTION, ANTIRETROVIRAL THERAPY AND CARDIOVASCULAR RISK
1934PDF: 825HTML: 3689 -
UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)
4328Suppl. Files: 1218PDF: 1130Html: 263 -
THE Co-Occurrence of Jak2/Calr-Positive Myeloproliferative Disorder and Bcr-Abl-Positive Chronic Myelogenous Leukaemia Treated with Combination of Tyrosine Kinase Inhibitors and Ruxolitinib. Dual Myeloid Disorder Treated with Two Drug Association
1153PDF: 1270HTML: 119 -
THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION. Clinical Evaluation of T-AML
2075PDF: 868HTML: 257 -
TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS
4473PDF: 1800HTML: 1122 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1658PDF: 1104HTML: 478 -
TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment
2230PDF: 1620HTML: 681 -
HIV-ASSOCIATED VENOUS THROMBOEMBOLISM
4581PDF: 1521HTML: 8537 -
SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a case report and review of ABL kinase involvement in viral infection CML and COVID-19
3367PDF: 1587HTML: 477 -







